Merck & Co. Inc. (NYSE:MRK) chief executive officer Ken Frazier said Oct 28, that the drugmaker was on track to deliver the $2.5 billion in annual cost savings that he promised to Wall Street. “Last October, we launched a multiyear initiative to transform Merck and build a platform for sustained future growth,” Frazier said in…
The Charles Schwab Corporation (NYSE:SCHW) is continuing to fight back against former brokers who leave its ranks. In one of its most recent actions, the firm filed suit last month against a Tampa, Fla.-based registered investment adviser, Camelot Wealth Management. Schwab accused the RIA, which was founded earlier this year by former Schwab branch manager…
“A common thread in our discussions (with supermarket industry leaders) has been declining Woolworths in-store execution,” said Morgan Stanley (NYSE:MS) analyst Tom Kierath. “Rising out of stocks, declining fresh food displays and tired stores were comments of note,” said Mr Kierath, who has cut his share price target from $31 to $30 and reduced his…
Exxon Mobil (NYSE:XOM) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.89 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.73 by $0.16. The company had revenue of $107.50 million for the quarter, compared to the consensus estimate of $105.50 billion. During the same quarter last…
Alpha Natural Resources, Inc. (NYSE:ANR) on Oct. 30 said its third-quarter loss narrowed, helped by reduced costs. The coal producer’s performance topped analysts’ estimates. ANR lost $185 million, or 84 cents per share, for the three months ended Sept. 30. That compares with a loss of $458.2 million, or $2.07 per share, a year ago….
Geron Corp (NASDAQ:GERN) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $160 thousand versus the consensus estimate of $240 thousand. The company also announced that the U.S. Food and Drug Administration (FDA) has removed the full clinical hold on Geron’s investigational new drug (IND)…
